

February 6, 2023
Web Announcement 2998

Drug Use Review (DUR) Board Approves Changes Effective February 6, 2023.

The Nevada Medicaid Drug Use Review (DUR) Board met on October 20, 2022, and voted to adopt the following changes effective February 6, 2023:

Drug Class/Program	Changes
Anti-Fungal Agents	Addition of new clinical criteria to Vivjoa [®] (oteseconazole)
H. pylori Agents	Addition of new clinical criteria to Voquezna Dual Pak [®] (vonoprazan/amoxicillin) and Voquezna Triple Pak [®] (vonoprazan/amoxicillin/clarithromycin)
Antivirals, CMV Agents	Addition of new clinical criteria to Livtency [®] (maribavir)
Copper Chelators	Addition of new clinical criteria to Cuvrior [®] (trientine tetrahydrochloride)
Pyruvate Kinase Activators	Addition of new clinical criteria to Pyrukynd [®] (mitapivat)
Narcolepsy Agents	Updates to clinical criteria to Provigil [®] (modafinil) and Nuvigil [®] (armodafinil)
Anti-Parkinson Agents	Addition of new clinical criteria to Kynmobi [®] (apomorphine)
RNAi Agents	Addition of new clinical criteria for Amvuttra (vutrisiran)
Immunomodulators	Updates to existing clinical criteria

Androgens	Addition of clinical criteria to oral testosterone agents Updates to clinical criteria for topical androgenic agents Updates to Gender Edits
Ophthalmic human nerve growth factors	Addition of clinical criteria to Oxervate® (cenegermin-bkbj)

Prior Authorization forms may be found on the pharmacy webpage
<https://nevadamedicaid.magellanrx.com/provider/forms>